NEWS

WIRES

OTHER

SDIX Collaborates with Banyan Biomarkers in Work to Detect Traumatic Brain Injury

The partnership calls for SDIX to collaborate with Banyan on the development of antibodies and immuno-solutions that include:

• custom monoclonal and polyclonal antibody development
• cell line banking and cryostorage
• antibody production and purification - in vivo and in vitro

Dr. Walid Qoronfleh, SDIX Executive Director, Life Sciences, said, "We look forward to working with Banyan Biomarkers as they continue their breakthrough work addressing the unmet clinical needs for detecting TBI. We believe our twenty years of experience in providing immuno-solutions; from antibody to assay development, as well as our in vitro diagnostics expertise make SDIX a valuable partner for companies like Banyan."

Mr. Fran DiNuzzo, SDIX President and CEO said, "We appreciate the opportunity to collaborate on this critical biomarker project with Banyan to help save and improve the lives of patients with brain injuries, including the potential of helping the brave men and women serving in our armed forces."

"We look forward to working with SDIX on the development of antibodies and immuno-solutions," stated Jackson Streeter, MD, CEO of Banyan Biomarkers. "This is an important step in the discovery of diagnostics and treatments for TBI and other neurological disorders."

According to the Centers for Disease Control (CDC), at least 1.7 million suffer a traumatic brain injury (TBI) in the United States annually. That's more than the number diagnosed with the top five cancers combined according to National Cancer Institute (NCI) statistics. Of those individuals, about 52,000 die, 275,000 are hospitalized, and 1.365 million are treated and released from an emergency department. The International Brain Injury Association (www.internationalbrain.org) reports 5.3 million Americans are living today with disabilities related to TBI.

About Banyan Biomarkers (www.banyanbio.com)

Banyan Biomarkers is the leader in developing in vitro diagnostic products to address unmet clinical needs for the detection of traumatic brain injury. The Company is focused on developing a simple point-of-care blood test that will be used by physicians to detect the presence and severity of brain trauma and improve the medical management of head injured patients. Banyan Biomarkers has a licensing agreement with the University of Florida for exclusive global use of technology related to this product. To learn more visit http://www.banyanbio.com.

About SDIX (www.sdix.com)

SDIX is a biotechnology company, expert at creating advantage by providing a broad range of quality, innovative and effective immuno-solutions to the pharmaceutical, biotechnology, diagnostics, and food safety markets. For nearly 20 years, SDIX has developed antibodies and reagents which advance its customers' immuno-based work - reducing time, labor, and costs while increasing accuracy and reliability of results.

SDIX offers a full suite of integrated immuno-solution capabilities including assay design, development, and production. In life science markets, SDIX capabilities are being used to help discover the mechanisms of disease, facilitate the development of new drugs, and provide mechanisms for rapid diagnosis.

This news release may contain forward-looking statements reflecting SDIX's current expectations. When used in this press release, words like "anticipate" , "could" , "enable" , "estimate" , "intend" , "expect" , "believe" , "potential" , "will" , "should" , "project" , "plan" and similar expressions as they relate to SDIX are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDIX at this time. Such risks and uncertainties include, without limitation, changes in demand for products, the application of our technologies to various uses, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDIX's public filings with the U.S. Securities and Exchange Commission.

SDIX
M. Walid Qoronfleh, PhD., MBA
302-456-6789
wqoronfleh@sdix.com